These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 34697502)

  • 1. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Patone M; Handunnetthi L; Saatci D; Pan J; Katikireddi SV; Razvi S; Hunt D; Mei XW; Dixon S; Zaccardi F; Khunti K; Watkinson P; Coupland CAC; Doidge J; Harrison DA; Ravanan R; Sheikh A; Robertson C; Hippisley-Cox J
    Nat Med; 2021 Dec; 27(12):2144-2153. PubMed ID: 34697502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
    Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
    Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
    Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study.
    Kim JW; Kim YG; Park YC; Choi S; Lee S; Min HJ; Kim MJ
    J Korean Med Sci; 2022 Feb; 37(7):e58. PubMed ID: 35191234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.
    Kaulen LD; Doubrovinskaia S; Mooshage C; Jordan B; Purrucker J; Haubner C; Seliger C; Lorenz HM; Nagel S; Wildemann B; Bendszus M; Wick W; Schönenberger S
    Eur J Neurol; 2022 Feb; 29(2):555-563. PubMed ID: 34668274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
    PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
    Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
    Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach.
    Choi MJ; Na Y; Hyun HJ; Nham E; Yoon JG; Seong H; Seo YB; Choi WS; Song JY; Kim DW; Kim YE; Jung J; Cheong HJ
    Clin Microbiol Infect; 2024 May; 30(5):646-652. PubMed ID: 38101473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study.
    Shasha D; Bareket R; Sikron FH; Gertel O; Tsamir J; Dvir D; Mossinson D; Heymann AD; Zacay G
    Clin Microbiol Infect; 2022 Jan; 28(1):130-134. PubMed ID: 34592420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.